Abstract
BackgroundPeripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is a heterogeneous group of aggressive T-cell lymphomas with poor treatment outcomes. The aim of this study was to evaluate whether lymphopenia at diagnosis would have an adverse effect on survival in patients with PTCL-NOS treated with anthracycline-containing chemotherapy.MethodsA total of 118 patients with PTCL-NOS treated with anthracycline-containing chemotherapy from 4 Korean institutions were included.ResultsThirty-six patients (30.5%) had a low absolute lymphocyte count (ALC, < 1.0 × 109/L) at diagnosis. Patients with lymphopenia had shorter overall survival (OS) and progression-free survival (PFS) rates compared with patients with high ALCs (P = 0.003, P = 0.012, respectively). In multivariate analysis, high-intermediate/high-risk International Prognostic Index (IPI) scores and lymphopenia were both associated with shorter OS and PFS. Treatment-related mortality was 25.0% in the low ALC group and 4.8% in the high ALC group (P = 0.003). In patients considered high-intermediate/high-risk based on IPI scores, lymphopenia was also associated with shorter OS and PFS (P = 0.002, P = 0.001, respectively).ConclusionThis study suggests that lymphopenia could be an independent prognostic marker to predict unfavorable OS and PFS in patients with PTCL-NOS treated with anthracycline-containing chemotherapy and can be used to further stratify high-risk patients using IPI scores.
Highlights
Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is a heterogeneous group of aggressive T-cell lymphomas with poor treatment outcomes
Because there is no information on the role of lymphopenia at diagnosis of Peripheral T-cell lymphomas (PTCL)-NOS, we evaluated its prognostic value in the patients with PTCL-NOS treated with similar chemotherapy regimens
The objective of this study was to retrospectively investigate whether lymphopenia is a predictive marker for survival in patients with PTCL-NOS treated with anthracycline-containing chemotherapy
Summary
Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is a heterogeneous group of aggressive T-cell lymphomas with poor treatment outcomes. Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), is the most common heterogeneous subgroup of PTCL because it includes lymphomas with no definitive clinical or biologic profile and it cannot be classified into a specific subtype [3]. Because previous prognostic markers, such as IPI, have been based on information from all patients with PTCL-NOS regardless of chemotherapy regimen used, the role of IPI needs to be evaluated in patients treated with similar chemotherapy regimens. This would allow for identification of additional simple prognostic markers in the same population of patients
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call